Tensive, a clinical-stage medical device company based in Milan, has entered into a groundbreaking agreement with the European Investment Bank (EIB) for a convertible loan of up to €20 million. This financial boost is aimed at propelling the development, regulatory approval, manufacturing scale-up, and commercialization of its innovative REGENERA bioresorbable breast implant.
Strategic Financing Breakdown
This financing represents a significant portion of Tensive’s ambitious €40 million funding plan, which is essential for achieving CE Mark approval and launching REGENERA in the European market. To complete the remaining financial requirements, Tensive is actively seeking additional equity investments that will support both development and launch initiatives in Europe and the United States.
The loan will be disbursed in two tranches of €8 million and €12 million, each with a 20-year maturity from the date of drawdown. These funds will facilitate research and development, clinical studies, CE marking, and the scaling up of manufacturing processes to ensure commercial readiness. However, access to these funds is contingent on meeting specific financial and contractual conditions.
Support from the European Commission
This financing initiative is backed by the European Commission’s InvestEU program, which provides Tensive with a less dilutive source of capital. This support is designed to encourage further investments from institutional and strategic investors, thereby enhancing the company’s capital structure and potential for growth.
Innovative Product Development
Tensive is at the forefront of medical innovation, focusing on the development of bioresorbable scaffolds such as REGENERA and SOFTAG for breast reconstruction and tissue marking. The REGENERA implant is specifically engineered to be placed during breast-conserving lumpectomy surgeries. It occupies the space left after tumor removal, allowing the patient’s own tissue to gradually grow into the scaffold. This unique design aims to restore breast volume and shape without necessitating a permanent implant or additional reconstructive surgeries.
Positive Clinical Outcomes
Recent developments have shown promising results from Tensive’s ongoing pivotal clinical trial involving 94 patients. As of the latest update, 87 of these patients have surpassed 12 months of follow-up, with 30 reaching the 24-month mark. The data indicates that 94.2% of evaluable cases achieved good to excellent cosmetic outcomes at the 12-month interval, alongside high levels of surgeon satisfaction and statistically significant improvements in patient-reported satisfaction regarding breast and cancer-related concerns. Notably, REGENERA has not interfered with oncologic imaging, a crucial aspect for patients undergoing cancer treatment.
Long-Term Success Indicators
The five-year follow-up from Tensive’s first-in-human study highlights sustained volume replacement and vascularization at the implant site, confirming the gradual resorption of the scaffold and the absence of capsule formation. This evidence supports the long-term viability of the REGENERA implant as a reconstruction option.
Future Expectations
Tensive anticipates receiving the first European regulatory approval for REGENERA as early as 2027. With approximately 1.6 million women annually lacking suitable reconstruction options following lumpectomy, Tensive aims to position REGENERA as a seamless, one-step solution that integrates effortlessly into existing surgical workflows. This approach seeks to simplify the complexities often associated with traditional breast reconstruction methods.
Leadership Insights
Dr. Sanjay Kakkar, CEO of Tensive, expressed confidence in the EIB’s commitment, stating, “The EIB has examined our clinical evidence and our regulatory file in detail and has committed €20 million to enable us to take REGENERA from our recently reported positive pivotal clinical results to a product in the hands of European surgeons. This commitment anchors and catalyzes our ongoing equity financing. We are one step closer to offering the first natural, lasting solution to women who today have no viable options for reconstruction after breast cancer lumpectomy.”
Moreover, Gelsomina Vigliotti, Vice President of the EIB, highlighted the importance of this investment in fostering European innovation in healthcare, particularly in women’s health. She noted that this financing would help Tensive advance its promising regenerative technology, addressing significant unmet medical needs in breast cancer care while simultaneously enhancing Europe’s capacity to develop high-value medical technologies.
Conclusion
Tensive’s strategic collaboration with the EIB marks a pivotal moment in the development of bioresorbable breast implants. This funding not only propels Tensive closer to commercializing REGENERA but also underscores the potential for innovative solutions in women’s healthcare. With positive clinical outcomes and a clear path to regulatory approval, Tensive is well-positioned to redefine breast reconstruction options for women worldwide.
- Tensive secures €20 million from EIB to advance REGENERA implant.
- Financing aims to support regulatory approval and manufacturing scale-up.
- Positive clinical trial results indicate high patient satisfaction and surgeon confidence.
- REGENERA offers a viable, bioresorbable solution for breast reconstruction.
- Anticipated European regulatory approval could be achieved by 2027.
Read more → pulse2.com